In the Original Investigation titled “Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study,”1 published online December 19, 2018, and in the February print issue of JAMA Psychiatry, there was an error in a 95% CI in the Results section of the abstract and the text. The 95% CI for the effect size for the insomnia score should be −0.61 to −0.02, not −0.65 to 0.02. The article has been corrected online.
Reference
- 1.Latif ZE, Šaltytė Benth J, Solli KK, et al. Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: a randomized clinical trial and follow-up study [published online December 19, 2018]. JAMA Psychiatry. doi: 10.1001/jamapsychiatry.2018.3537 [DOI] [PMC free article] [PubMed] [Google Scholar]